Insurance companies are increasingly restricting coverage for GLP-1 medications, impacting patient access and affordability.

One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?

Results from a Phase II trial (NCT06640972) showed that patients treated with RDX-002 experienced significant reductions in ...

Overweight patients waiting for operations could safely use a particular type of weight-loss treatment to reduce the risk of ...

The weight loss conversation has been transformed in recent years by the rise of GLP-1 medications—drugs originally developed for diabetes that are now being used to help people lose significant ...

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...

The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.

GLP-1 receptor agonists linked to modestly increased risk for incident DR, but tied to reduced risk for certain complications of DR.

The rapid adoption of GLP-1 receptor agonists has fundamentally altered obesity management, with these medications now ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

GLP-1 weight-loss drugs have already taken the Europe storm, altering consumer eating habits. Even the eating habits of GLP-1 ...

GLP-1 agonists are medications that primarily treat type 2 diabetes and obesity. However, recent studies suggest they can lower blood pressure, reduce inflammation and improve lipid disorders.